Ultimovacs ASA - Asset Resilience Ratio
Ultimovacs ASA (ULTI) has an Asset Resilience Ratio of 0.31% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ULTI strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2022)
This chart shows how Ultimovacs ASA's Asset Resilience Ratio has changed over time. See Ultimovacs ASA balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ultimovacs ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ULTI market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 0% |
| Short-term Investments | Nkr961.00K | 0.31% |
| Total Liquid Assets | Nkr961.00K | 0.31% |
Asset Resilience Insights
- Limited Liquidity: Ultimovacs ASA maintains only 0.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ultimovacs ASA Industry Peers by Asset Resilience Ratio
Compare Ultimovacs ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Ascletis Pharma Inc
F:2VJ |
Biotechnology | 22.13% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Ultimovacs ASA (2016–2022)
The table below shows the annual Asset Resilience Ratio data for Ultimovacs ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 1.34% | Nkr6.81 Million ≈ $716.40K |
Nkr509.67 Million ≈ $53.63 Million |
+0.24pp |
| 2021-12-31 | 1.09% | Nkr7.17 Million ≈ $754.39K |
Nkr655.54 Million ≈ $68.98 Million |
-0.56pp |
| 2020-12-31 | 1.66% | Nkr8.77 Million ≈ $922.86K |
Nkr529.72 Million ≈ $55.74 Million |
+0.17pp |
| 2019-12-31 | 1.49% | Nkr7.12 Million ≈ $748.70K |
Nkr478.04 Million ≈ $50.30 Million |
-1.78pp |
| 2018-12-31 | 3.27% | Nkr6.21 Million ≈ $653.37K |
Nkr189.86 Million ≈ $19.98 Million |
+0.45pp |
| 2017-12-31 | 2.82% | Nkr5.04 Million ≈ $530.04K |
Nkr178.82 Million ≈ $18.82 Million |
-3.54pp |
| 2016-12-31 | 6.36% | Nkr5.25 Million ≈ $552.98K |
Nkr82.63 Million ≈ $8.69 Million |
-- |
About Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.